%0 Journal Article %T Cranberry versus placebo in the prevention of urinary infections in multiple sclerosis: a multicenter, randomized, placebo-controlled, double-blind trial %+ Physiologie et physiopathologie de la motricité chez l'homme %+ Unité de Parasitologie %+ Unité de Recherche sur les Maladies Infectieuses et Tropicales Emergentes (URMITE) %+ Infections Parasitaires : Transmission, Physiopathologie et Thérapeutiques (IP-TPT) %+ Equipe Résidente de Recherche en Infectiologie Tropicale %+ Service de médecine physique et de réadaptation %+ Unité de traitement des signaux Biomédicaux (UTSB) %+ Centre mutualiste de Kerpape %+ Service de médecine physique et de réadaptation [ CHU Raymond-Poincaré] %+ Centre d'Investigation Clinique [Rennes] (CIC) %+ Service de Pharmacologie [Rennes] %+ Comportement et noyaux gris centraux = Behavior and Basal Ganglia [Rennes] %A Gallien, Philippe %A Amarenco, Gérard %A Benoit, Nicolas %A Bonniaud, Véronique %A Donzé, Cécile %A Kerdraon, Jacques %A Seze, Marianne, De %A Denys, Pierre %A Renault, Alain %A Naudet, Florian %A Reymann, Jean Michel %< avec comité de lecture %@ 1352-4585 %J Multiple Sclerosis Journal %I SAGE Publications %V 20 %N 9 %P 1252--1259 %8 2014-01-08 %D 2014 %R 10.1177/1352458513517592 %M 24402038 %K Multiple sclerosis %K cranberry (Vaccinium macrocarpon) %K neurogenic bladder %K urinary tract infection %Z Life Sciences [q-bio]Journal articles %X OBJECTIVE: Our aim was to assess the usefulness of cranberry extract in multiple sclerosis (MS) patients suffering from urinary disorders. METHODS: In total, 171 adult MS outpatients with urinary disorders presenting at eight centers were randomized (stratification according to center and use of clean intermittent self-catheterization) to cranberry versus placebo in a 1-year, prospective, double-blind study that was analyzed using a sequential method on an intent-to-treat basis. An independent monitoring board analyzed the results of the analyses each time 40 patients were assessed on the main endpoint. Cranberry extract (36 mg proanthocyanidins per day) or a matching placebo was taken by participants twice daily for 1 year. The primary endpoint was the time to first symptomatic urinary tract infection (UTI), subject to validation by a validation committee. RESULTS: The second sequential analyses allowed us to accept the null hypothesis (no difference between cranberry and placebo). There was no difference in time to first symptomatic UTI distribution across 1 year, with an estimated hazard ratio of 0.99, 95% CI [0.61, 1.60] (p = 0.97). Secondary endpoints and tolerance did not differ between groups. CONCLUSION: Taking cranberry extract versus placebo twice a day did not prevent UTI occurrence in MS patients with urinary disorders. Trial Registration NCT00280592. %G English %L hal-01147022 %U https://univ-rennes.hal.science/hal-01147022 %~ SSA %~ UPMC %~ UNIV-RENNES1 %~ CNRS %~ UNIV-AMU %~ APHP %~ HL %~ CIC %~ CIC203 %~ STATS-UR1 %~ CNGC %~ UR1-UFR-SVE %~ UR1-HAL %~ UR1-SDV %~ TEST-UNIV-RENNES %~ TEST-UR-CSS %~ UNIV-RENNES %~ SORBONNE-UNIVERSITE %~ UR1-BIO-SA %~ ALLIANCE-SU %~ UNIV-CATHOLILLE %~ ICL %~ FMMS